Adrenoleukodystrophy in the era of newborn screening
Authors:
- Molly O. RegelmannMRMolly O. Regelmann
- 1 February 2020
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Endocrinology, Diabetes and Obesity
- Vol. 27 (1) , 47-55
Abstract
Purpose of review: Adrenoleukodystrophy (ALD) is a peroxisomal disorder with varying clinical presentations, including adrenal insufficiency, neurologic disease, and testicular dysfunction. The present review is intended to describe the current knowledge of the pathophysiology of ALD and provide an update regarding newborn screening, diagnosis, monitoring, and treatment. Recent findings: New York State initiated newborn screening for ALD on December 30, 2013. Successful ALD newborn screening has led to its addition on other state newborn screens and recommendations for universal screening. Initial incidence reports, based on newborn screening, suggest ALD may be more common than previously described. The Pediatric Endocrine Society has published guidance for monitoring newborn males with ALD and case reports suggest biochemical adrenal insufficiency can be present during early infancy. Allogeneic hematopoietic stem cell transplant and gene therapy have been effective at halting the progression of cerebral ALD. Summary: Early diagnosis and monitoring for progression of ALD can prevent adrenal crisis and treat the cerebral form of the disease. Initial guidelines for surveillance are likely to evolve as newborn screening not only aids in early detection and therapeutic interventions for ALD, but also expands our knowledge of the natural history of ALD.Keywords
This publication has 64 references indexed in Scilit:
- No evidence for the reversal of adrenal failure after hematopoietic cell transplantation in X-linked adrenoleukodystrophyBone Marrow Transplantation, 2012
- X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and managementOrphanet Journal of Rare Diseases, 2012
- Current and Future Pharmacological Treatment Strategies in X‐Linked AdrenoleukodystrophyBrain Pathology, 2010
- Newborn screening for X-linked adrenoleukodystrophy (X-ALD): Validation of a combined liquid chromatography–tandem mass spectrometric (LC–MS/MS) methodMolecular Genetics and Metabolism, 2009
- Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophyHuman Molecular Genetics, 2008
- Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screeningThe Journal of Pediatrics, 2005
- Monozygotic twins with X‐linked adrenoleukodystrophy and different phenotypesAnnals of Neurology, 2001
- X-Linked Adrenoleukodystrophy (ALD): A Novel Mutation of the ALD Gene in 6 Members of a Family Presenting with 5 Different PhenotypesBiochemical and Biophysical Research Communications, 1994
- A Two-Year Trial of Oleic and Erucic Acids (“Lorenzo's Oil”) as Treatment for AdrenomyeloneuropathyNew England Journal of Medicine, 1993
- Qualitative alteration in substrate specificity of mitochondrial monoamine oxidase in brainJournal of Neurochemistry, 1976